A campaign of mass drug administration with artemisinin-piperaquine to antimalaria in Trobriand Islands.

Abstract

We conducted a study on the Trobriand Islands of Papua New Guinea (PNG) in 2018 to verify the safety and efficacy of the artemisinin-piperaquine (AP) mass drug administration (MDA) campaign in regions with moderate to high mixed malaria transmission. Based on the natural topography of the Trobriand Islands, 44,855 residents from 92 villages on the islands were enrolled and divided into the main and outer islands. Three rounds of MDA were conducted using grid-based management. The primary endpoint was the coverage rate. Adverse reactions, parasitemia, and malaria morbidity were the secondary endpoints. There were 36,716 people living in 75 villages on the main island, and the MDA coverage rate was 92.58-95.68%. Furthermore, 8,139 people living in 17 villages on the outer islands had a coverage rate of 94.93-96.11%. The adverse reactions were mild in both groups, and parasitemia decreased by 87.2% after one year of surveillance. The average annual malaria morbidity has decreased by 89.3% after the program for four years. High compliance and mild adverse reactions indicated that the MDA campaign with AP was safe. The short-term effect is relatively ideal, but the evidence for long-term effect evaluation is insufficient.

• Authors: Guoming Li, Shaoqin Zheng, Zhenyan Zhang, Yanshan Hu, Nansong Lin, Nadia Julie, Lei Shu, Liwei Sun, Hongying Zhang, Yueming Yuan, Yuan Liang, Zhengjie Yu, Wei Xie, Ridley Mwaisiga, Jacob Morewaya, Qin Xu, Jianping Song, Changsheng Deng
• Journal: Preventive medicine reports (Prev Med Rep) Vol. 32 Pg. 102154 (Apr 2023) ISSN: 2211-3355 [Print] United States
• PMID: 36852307 (Publication Type: Journal Article)
• Copyright: © 2023 The Authors.